سعر فروسيتور 5 مجم 30 قرص 2024

Rosuvastatin 5 mg film-coated tablets, 30 tablets (3 strips) per pack, by Future Pharmaceutical Industries (FPI) for Tabuk Pharmaceutical Manufacturing Company (Egypt); statin for hypercholesterolaemia and cardiovascular risk reduction.

• To reduce the risk of major adverse cardiovascular events (CV death, nonfatal MI, nonfatal stroke, arterial revascularisation) in adults at increased risk.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolaemia, and to slow progression of atherosclerosis.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjunct to diet and exercise to reduce LDL-C in heterozygous familial hypercholesterolaemia (adults and children aged 8 years and older) and homozygous familial hypercholesterolaemia (adults and children aged 7 years and older).Population: Adults and pediatric patientsDailyMed (U.S. National Library of Medicine)

• Most common (2% or more and above placebo): headache, nausea, myalgia, asthenia and constipation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Acute liver failure or decompensated cirrhosis.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to rosuvastatin or any excipient (rash, pruritus, urticaria, angioedema reported).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis (with acute kidney injury, rarely fatal); risk factors include age 65 or older, uncontrolled hypothyroidism, renal impairment, interacting drugs, higher dosage (40 mg) and Asian ancestry; discontinue if CK is markedly elevated or myopathy is suspected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic dysfunction: transaminase increases and rare hepatic failure; consider liver enzyme testing before starting and as indicated; stop if serious liver injury occurs.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• CyclosporineIncreased rosuvastatin exposure and myopathy risk; do not exceed 5 mg once daily.DailyMed (U.S. National Library of Medicine)
• GemfibrozilAvoid; if unavoidable, initiate at 5 mg and do not exceed 10 mg once daily.DailyMed (U.S. National Library of Medicine)
• Warfarin (coumarin anticoagulants)Obtain INR before starting and monitor frequently until stable.DailyMed (U.S. National Library of Medicine)

• Discontinue when pregnancy is recognised (or consider the patient's ongoing therapeutic needs); may cause fetal harm based on mechanism of action.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Rosuvastatin is present in human milk; breastfeeding is not recommended during treatment.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Rosuvastatin: Competitive inhibition of HMG-CoA reductase reduces hepatic cholesterol synthesis and increases LDL-receptor expression.